Literature DB >> 30782378

Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?

Roberto Ferrara1, Caroline Caramella2, Benjamin Besse3, Stéphane Champiat4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30782378     DOI： 10.1016/j.jtho.2018.12.011

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  11 in total

Review 1.  Considerations for designing preclinical cancer immune nanomedicine studies.

Authors:  Wen Jiang; Yifan Wang; Jennifer A Wargo; Frederick F Lang; Betty Y S Kim
Journal:  Nat Nanotechnol       Date:  2020-12-21       Impact factor: 39.213

Review 2.  Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives.

Authors:  Wenxin Luo; Zhoufeng Wang; Ting Zhang; Lan Yang; Jinghong Xian; Yalun Li; Weimin Li
Journal:  Precis Clin Med       Date:  2021-12-02

Review 3.  Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy.

Authors:  Daniele Lecis; Sabina Sangaletti; Mario P Colombo; Claudia Chiodoni
Journal:  Cancers (Basel)       Date:  2019-05-04       Impact factor: 6.639

4.  Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors.

Authors:  Po-Hsin Lee; Tsung-Ying Yang; Kun-Chieh Chen; Yen-Hsiang Huang; Jeng-Sen Tseng; Kuo-Hsuan Hsu; Yu-Chen Wu; Ko-Jiunn Liu; Gee-Chen Chang
Journal:  Sci Rep       Date:  2021-04-30       Impact factor: 4.379

5.  Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).

Authors:  Biagio Ricciuti; Greg Jones; Mariano Severgnini; Joao V Alessi; Gonzalo Recondo; Marissa Lawrence; Tim Forshew; Christine Lydon; Mizuki Nishino; Michael Cheng; Mark Awad
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

6.  CT-Based Peritumoral and Intratumoral Radiomics as Pretreatment Predictors of Atypical Responses to Immune Checkpoint Inhibitor Across Tumor Types: A Preliminary Multicenter Study.

Authors:  Shuai He; Yuqing Feng; Qi Lin; Lihua Wang; Lijun Wei; Jing Tong; Yuwei Zhang; Ying Liu; Zhaoxiang Ye; Yan Guo; Tao Yu; Yahong Luo
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

7.  Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy.

Authors:  Jeffrey C Thompson; Erica L Carpenter; Benjamin A Silva; Jamie Rosenstein; Austin L Chien; Katie Quinn; Carin R Espenschied; Allysia Mak; Lesli A Kiedrowski; Martina Lefterova; Rebecca J Nagy; Sharyn I Katz; Stephanie S Yee; Taylor A Black; Aditi P Singh; Christine A Ciunci; Joshua M Bauml; Roger B Cohen; Corey J Langer; Charu Aggarwal
Journal:  JCO Precis Oncol       Date:  2021-03-19

Review 8.  Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations.

Authors:  Roberto Ferrara; Diego Signorelli; Claudia Proto; Arsela Prelaj; Marina Chiara Garassino; Giuseppe Lo Russo
Journal:  Transl Lung Cancer Res       Date:  2021-06

Review 9.  [Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics].

Authors:  Xinghao Ai; Yong Cai; Qian Chu; Chengbo Han; You Lu; Songbing Qin; Lin Wu; Conghua Xie; Zhiyong Yuan; Wenzhao Zhong; Xiaoxia Zhu; Joe Y Chang; Zhengfei Zhu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-06-20

10.  RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.

Authors:  Romain Cohen; Jaafar Bennouna; Aurélia Meurisse; Christophe Tournigand; Christelle De La Fouchardière; David Tougeron; Christophe Borg; Thibault Mazard; Benoist Chibaudel; Marie-Line Garcia-Larnicol; Magali Svrcek; Dewi Vernerey; Yves Menu; Thierry André
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.